Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma

Leuk Lymphoma. 2019 Dec;60(13):3320-3323. doi: 10.1080/10428194.2019.1627540. Epub 2019 Jun 17.

Authors

Milos D Miljkovic¹, Mark Roschewski¹, Kieron Dunleavy^{1

2}, Wyndham H Wilson¹

Affiliations

¹ Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
² Department of Medicine, The George Washington University, Washington, DC, USA.

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Cyclin-Dependent Kinases / antagonists & inhibitors
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance, Neoplasm
Flavonoids / administration & dosage*
Flavonoids / adverse effects
Humans
Infusions, Intravenous / methods
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / pathology
Lymphoma, Mantle-Cell / drug therapy*
Lymphoma, Mantle-Cell / pathology
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / pathology
Piperidines / administration & dosage*
Piperidines / adverse effects
Protein Kinase Inhibitors / administration & dosage*
Protein Kinase Inhibitors / adverse effects
Treatment Outcome
Young Adult

Substances

Flavonoids
Piperidines
Protein Kinase Inhibitors
alvocidib
Cyclin-Dependent Kinases

Grants and funding